Sumedha Sudhaman1, Kameshwar Prasad2, Madhuri Behari2, Uday B Muthane3, Ramesh C Juyal4, B K Thelma1. 1. Department of Genetics, University of Delhi South Campus, New Delhi, India. 2. Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. 3. Parkinson's and Ageing Research Foundation, Bengaluru, Karnataka, India. 4. Regional Center for Biotechnology, Faridabad, Haryana, India.
Abstract
BACKGROUND: Mutations in known genes for inherited forms of Parkinson's disease (PD) account for <30% of familial PD (FPD) implying that more causal gene(s) remain to be identified. We attempted to discover the putative causal variant in an Indian family with autosomal-recessive juvenile Parkinsonism (ARJP), tested negative for mutations in PARK2, PINK1 and DJ1. METHODS: Whole exomes of two affected siblings were sequenced. Variants prioritised were screened for segregation with disease in the family by targeted sequencing. Gene thus identified was screened for index/additional exonic mutations, if any, in an independent PD cohort by PCR sequencing. Variants observed were functionally validated in differentiated PC12 cells. RESULTS: A novel homozygous frameshift mutation, c.89_90insGTCGCCCC in exon 1 of podocalyxin-like gene (PODXL, 7q32-33), resulting in loss of protein, segregated with disease in the family. Mutant allele was absent in 186 healthy controls screened by PCR sequencing and in control exomes available in the laboratory and public databases. Screening of additional 212 sporadic and 68 FPD cases identified three novel heterozygous missense variants namely c.1285C>A, c.1118G>A and c.881G>A in three unrelated cases. Significant differences in neurite branching and length (p<0.0001) were observed in PC12 cells with wild-type and mutant constructs. CONCLUSIONS: Based on the genetic and functional evidence in this study and literature support on the role of PODXL in neural development, a novel frameshift mutation in PODXL seems to be the likely cause of ARJP in this family. This is the first report suggesting the possible role of a neurodevelopmental pathway in PD aetiology. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Mutations in known genes for inherited forms of Parkinson's disease (PD) account for <30% of familial PD (FPD) implying that more causal gene(s) remain to be identified. We attempted to discover the putative causal variant in an Indian family with autosomal-recessive juvenile Parkinsonism (ARJP), tested negative for mutations in PARK2, PINK1 and DJ1. METHODS: Whole exomes of two affected siblings were sequenced. Variants prioritised were screened for segregation with disease in the family by targeted sequencing. Gene thus identified was screened for index/additional exonic mutations, if any, in an independent PD cohort by PCR sequencing. Variants observed were functionally validated in differentiated PC12 cells. RESULTS: A novel homozygous frameshift mutation, c.89_90insGTCGCCCC in exon 1 of podocalyxin-like gene (PODXL, 7q32-33), resulting in loss of protein, segregated with disease in the family. Mutant allele was absent in 186 healthy controls screened by PCR sequencing and in control exomes available in the laboratory and public databases. Screening of additional 212 sporadic and 68 FPD cases identified three novel heterozygous missense variants namely c.1285C>A, c.1118G>A and c.881G>A in three unrelated cases. Significant differences in neurite branching and length (p<0.0001) were observed in PC12 cells with wild-type and mutant constructs. CONCLUSIONS: Based on the genetic and functional evidence in this study and literature support on the role of PODXL in neural development, a novel frameshift mutation in PODXL seems to be the likely cause of ARJP in this family. This is the first report suggesting the possible role of a neurodevelopmental pathway in PD aetiology. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Rafiqua Ben El Haj; Wafaa Regragui; Rachid Tazi-Ahnini; Asmae Skalli; Naima Bouslam; Ali Benomar; Mohamed Yahyaoui; Ahmed Bouhouche Journal: Biomed Res Int Date: 2016-06-20 Impact factor: 3.411
Authors: Hee Gyung Kang; Moses Lee; Kyoung Boon Lee; Michael Hughes; Bo Sang Kwon; Sangmoon Lee; Kelly M McNagny; Yo Han Ahn; Jung Min Ko; Il-Soo Ha; Murim Choi; Hae Il Cheong Journal: Exp Mol Med Date: 2017-12-15 Impact factor: 8.718
Authors: Ryan F Townshend; Yue Shao; Sicong Wang; Chari L Cortez; Sajedeh Nasr Esfahani; Jason R Spence; K Sue O'Shea; Jianping Fu; Deborah L Gumucio; Kenichiro Taniguchi Journal: Front Cell Dev Biol Date: 2020-10-15